Clair Labs, a startup developing contact-free patient monitoring technology, announces its seed funding round, raising $9 million. The round is led by 10D, with participation of US-based SleepScore Ventures, which specializes in innovative sleep solutions, Israeli fund Maniv Mobility and London based tech fund Vasuki.
Follow Israel Hayom on Facebook and Twitter
Clair Labs's technology enables continuous, round-the-clock monitoring for physiological markers like heart rate, respiration, air flow, body temperature, SpO2 and more. The system also monitors behavioral markers, including sleep patterns, distress, tracking changes in the patient's position, detecting their intent to rise, among others. The data is fed to smart learning algorithms which in turn produce accurate evaluations and alerts.
The company was co-founded in 2018 by Adi Berenson (CEO) and Dr. Ran Margolin (CTO). The two met while filling key roles in Apple's product incubation group.
Berenson and Margolin lead a team developing remote patient monitoring systems based on proprietary technology for medical-grade acquisition of physiological markers without contact with the patient (contact-free). The company is targeting the remote patient monitoring and remote healthcare markets, which are expected to grow exponentially and revolutionize the way we consume healthcare.
"The idea for Clair Labs started with a vision of proactive, preventative medicine, which requires health monitoring that integrates into our lives when we are healthy, before diseases develop," said Berenson.
"As the COVID-19 pandemic erupted, we realized how critical effective and seamless monitoring truly is for care facilities, as well, as they are coping with overwhelming patient capacity and increasing disease rates. Continuous and ongoing patient monitoring will ensure early detection of deterioration or alarming infections. It will help reduce adverse events such as patients falling, pressure ulcers and more. In the future, contact-free monitoring will enable remote supervision of patients in home hospitalization."
The company's prototypes are currently undergoing clinical trials at Tel Aviv Sourasky Medical Center and at the Assuta Sleep Medicine Institute. Later this year, the company is set to start pilots with leading sleep centers and hospitals in the United States.
